Follicular Lymphoma Pipeline, NDA Approvals, Clinical Trials Assessment, and Emerging Drugs (2023) | Companies – Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., Nordic Nanovector, and Others
DelveInsight’s report titled “Follicular Lymphoma Pipeline Insight 2023” offers extensive information on more than 50+ companies and over 50+ pipeline drugs in the field of Follicular Lymphoma research. The Follicular Lymphoma pipeline report encompasses detailed profiles of the pipeline drugs for Follicular Lymphoma, including information on Follicular Lymphoma clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Follicular Lymphoma emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Follicular Lymphoma pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Follicular Lymphoma clinical trial studies conducted for Follicular Lymphoma, any NDA approvals obtained for Follicular Lymphoma, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Follicular Lymphoma Pipeline treatment landscape of the report, click here @ Follicular Lymphoma Pipeline Outlook
Key Takeaways from the Follicular Lymphoma Pipeline Report
- DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
- The leading Follicular Lymphoma Companies in the market include Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc, Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others
- Promising Follicular Lymphoma Pipeline Therapies in the various stages of development include DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, GP2013, Epcoritamab, Venetoclax, Bendamustine, Mosunetuzumab (IV), Tocilizumab, Lenalidomide, Atezolizumab (MPDL3280A) [TECENTRIQ], and others
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The drug currently investigated in Phase III trials for the condition.
- Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology, jointly owned by Genmab and AbbVie Inc. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab (DuoBody®-CD3xCD20) is currently under investigation in multiple ongoing clinical studies including a Phase III study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular Lymphoma.
- Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in irreversible inactivation of the enzyme. The drug is currently under Phase III trial of the disease.
- Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in Phase II stage of development to treat Follicular lymphoma.
Follicular Lymphoma Overview
Follicular lymphoma is a form of cancer. It is a type of non-Hodgkin lymphoma (NHL), which is a group of related cancers that affect the lymphatic system (lymphomas). The lymphatic system functions as part of the immune system and helps to protect the body against infection and disease. It consists of a network of tubular channels (lymph vessels) that drain a thin watery fluid known as lymph from different areas of the body into the bloodstream.
For further information, refer to the detailed Follicular Lymphoma Unmet Needs, Follicular Lymphoma Market Drivers, and Market Barriers, click here for Follicular Lymphoma Ongoing Clinical Trial Analysis
Follicular Lymphoma Emerging Drugs Profile
- Tafasitamab: Incyte Corporation
- Epcoritamab: Genmab A/S
- Zanubrutinib – BeiGene
- Pembrolizumab: Merck & Co.
Follicular Lymphoma Pipeline Therapeutics Assessment
There are approx. 50+ Follicular Lymphoma companies which are developing the therapies for Follicular Lymphoma. The Follicular Lymphoma companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III.
Request a sample and discover the recent advances in Follicular Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Follicular Lymphoma Treatment Landscape
Follicular Lymphoma Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Fragile X Syndrome Therapeutics Market include-
Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc, Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
Dive deep into rich insights for drugs for Follicular Lymphoma Pipeline, click here @ Follicular Lymphoma Unmet Needs and Analyst Views
Scope of the Follicular Lymphoma Pipeline Report
- Coverage- Global
- Follicular Lymphoma Companies- Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc, Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others
- Follicular Lymphoma Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, GP2013, Epcoritamab, Venetoclax, Bendamustine, Mosunetuzumab (IV), Tocilizumab, Lenalidomide, Atezolizumab (MPDL3280A) [TECENTRIQ], and others.
- Follicular Lymphoma Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Follicular Lymphoma Mergers and acquisitions, Follicular Lymphoma Licensing Activities @ Follicular Lymphoma Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Follicular Lymphoma Executive Summary
- Follicular Lymphoma: Overview
- Follicular Lymphoma Pipeline Therapeutics
- Follicular Lymphoma Therapeutic Assessment
- Follicular Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Zanubrutinib – BeiGene
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Pembrolizumab: Merck & Co.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Follicular Lymphoma Key Companies
- Follicular Lymphoma Key Products
- Follicular Lymphoma- Unmet Needs
- Follicular Lymphoma- Market Drivers and Barriers
- Follicular Lymphoma- Future Perspectives and Conclusion
- Follicular Lymphoma Analyst Views
- Follicular Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment
